🚨Take this 15 min survey to shape the future of #Hepatology:
👉 survey.alchemer.eu/s3/91085482/...
🦠 #Microbiome-based mechanisms & biomarkers for improved patient stratification + prediction of therapeutic response in decompensated #Cirrhosis / #ACLF
⏳Survey closes on 17 May
@easlnews.bsky.social
19 April is #WorldLiverDay! What do you do to strengthen your own liver every day? #SolidHabitsStrongLiver
Establish these 4 habits 🥳:
👉 Eat healthy 🥦
👉 Move your body 🥎🎾🏃➡️
👉 Reduce alcohol🍷 ➡️ 🥛 (there's no "safe" amount of alcohol)
👉 Get your liver checked regularly 🩺🥼⚕️
@easlnews.bsky.social
🎥 The gut virome matters !🦠
Researchers at KU Leuven (@kuleuvenuniversity.bsky.social) found viral changes in the gut linked to #ACLF, #infections, and mortality - opening new paths for early detection and intervention.
💡 It’s not just bacteria
#Microbiome #Virome #LiverDisease
youtu.be/K9MIlhK4K5g
🎥 Antimicrobial resistance - the silent pandemic
@drlaedwards.bsky.social (KCL) explains why #AMR threatens global health, especially for liver patients, how #microbiome research may be part of the solution & why involving patients in research is so important
💡 youtu.be/pPcFoWD4iIU
#GlobalHealth
🎥 Can we predict liver failure before it happens?
Researchers at the University of Copenhagen are identifying biomarkers (e.g. metabolites) in a variety of samples to detect ACLF risk early - enabling potentially life-saving interventions.
#LiverFailure #ACLF #PrecisionMedicine
youtu.be/1s6Rp2If_-o
Register here for EASL Congress 2026 (required to attend the MICROB-PREDICT Consensus Conference): www.easlcongress.eu/2026-registr...
📣 Join the MICROB-PREDICT Consensus Conference in Barcelona (for #EASLCongress attendees only)
📅 27 May 2026
⏰ 15:30 – 18:30 h
Experts will discuss #microbiome mechanisms and biomarkers to improve patient stratification and therapeutic response in #cirrhosis and #ACLF.
@easlnews.bsky.social
Register here to attend EASL Congress (required to attend the MICROB-PREDICT Consensus Conference): www.easlcongress.eu/2026-registr...
A big step towards precision medicine!
🎥 youtu.be/pgrQVn8mPbk
Researchers at OUH are validating #biomarkers to predict which #cirrhosis patients may benefit from #albumin therapy - helping deliver the right treatment to the right patient
💡 Double-blind clinical ABL-Trial ongoing
#LiverDisease #ACLF
🧬 Metabolomics is unlocking new possibilities in personalised medicine!
In MICROB-PREDICT, researchers showed that urine & stool can reveal even more #biomarker insights than blood🩸, helping predict outcomes in severe #LiverDisease earlier.
Christophe Junot (CEA) on YouTube:
📽️ youtu.be/TYObOSu_r2w
New 📽️: Cristina López & Bryan Contreras present their findings on 9,10-DiHOME, a linoleic acid-derived #leukotoxin. This lipid mediator may increase susceptibility to bacterial infection in late-stage #cirrhosis
👉 youtu.be/9fIUZM7Df1E
#Inflammation #Immunosuppression #LiverSky
@idibaps.bsky.social
Alexandra Phillips (UCL) on pre-clinical research in animal models of #LiverFailure and #ACLF, showing how #albumin infusions reduce endotoxin sensitivity by modulating TLR4-driven #inflammation to protect against multi-organ injury.
🎥: youtu.be/SIi906R9DZI
@ucl.ac.uk
@rajivjalan.bsky.social
Feel free to join and "follow all" in our starter pack ☺️: go.bsky.app/4cMqxsU
🥳 Congratulations, David Tornai et al. from Maria Papp's team at the University of Debrecen! The paper has been viewed more than 625 times since its publication in Dec 2025 & is currently amongst the top-downloaded articles!
#SerumVillin #GutBarrier #ACLF
📰 onlinelibrary.wiley.com/doi/10.1111/...
🧪 Priority ahead: A strong push to reach 240 patients in the #ALBTRIAL - crucial for robust clinical validation and real patient impact
🏆 And congratulations to Aleksander Krag on the #HagedornPrize for groundbreaking work in early detection of #LiverDisease - an inspiration to the whole consortium
👏 Huge thanks to the SC + all team members for open discussions and constructive feedback. Now it’s time to roll up our sleeves & push hard toward the project finish line (Sept 2026). Delivering high-quality outputs to our funding agency (EU) is ambitious but absolutely achievable. We can do it! 🏃♀️🏃♂️
Across all WPs, we saw impressive progress - from clinical and genetic characterisation to #microbiome, multi #omics, experimental validation & systems #modelling. Major advances in #proteomics, #metabolomics, #biomarkers & prediction models - highlight the power of our multidisciplinary team. 🔬
🩺🧪🦠 Thank you, team MICROB-PREDICT, for a strong and successful 15th #SteeringCommittee Meeting. Two intense days with excellent science and great discussions - held in a time of shared grief as we remember #PeerBork from #EMBL 🖤, our esteemed colleague and mentor🕯️. We move forward with momentum! 💪
Prof. Peer Bork, EMBL Interim Director General, died on 16 January 2026. A remarkable scientist and leader, he played a pivotal role in MICROB-PREDICT, inspiring colleagues & mentees alike - leaving a lasting scientific legacy. Our heartfelt condolences to his family. Thank you for everything, Peer!
Save the date! We look forward to our upcoming steering committee (SC) meeting from 26-27 January 2026. We’ll hear about the results in all work packages and align the consortium's efforts for the next steps in our cross-disciplinary collaboration! @easlnews.bsky.social @horizoneu.bsky.social
Prices:
€60 €
45 - Students, unemployed, pensioners, over 65s, Friends of the CCCB
Registrations:
Course offered in both in-person and online formats. Register here .
www.cccb.org/es/actividad...
In 2026, the Universitat de Barcelona will collaborate again with the Centre de Cultura Contemporània de Barcelona (CCCB) to talk about "bodies, data, and the market - Reflections from bioethics" - don't miss it!
📅 26 February and 5, 12, 19 and 26 March 2026
🫖 Snuggle in with a cup of tea and a blanket over the holidays to read this year's MICROB-PREDICT publications - Wishing everyone relaxing winter holidays and a wonderful start into the New Year! ❄️
📖 microb-predict.eu/for-scientis...
@medblab.bsky.social
@easlnews.bsky.social
@ec.europa.eu
As the year draws to a close, we are wrapping up 2025 with gratitude, momentum, and a spirit of community at concentris. ✨
💡Curious about what’s next in 2026, and how these developments could support your work?
Read our latest #newsletter:
🔗 mailchi.mp/concentris/n...
👉 In this video, Dávid Tornai (MD, PhD) from Maria Papp's group at the University of Debrecen in Hungary presents the consortium's research on serum #villin-1, a tell-tale sign of #GutBarrier failure in cirrhotic patients with acute #decompensation via a graphical abstract.
📽️ youtu.be/URerer6AxxY
👏 New study from Dávid Tornai and colleagues 🎉: Serum #Villin1 is a promising non-invasive marker of #GutBarrier damage in #cirrhosis and #ACLF.
It rises with severity, predicts 90-day mortality, links to #inflammation, and has been validated in an independent cohort!
📜 doi.org/10.1111/apt....
📽️ Now online 🎧: lnkd.in/dJuMmsc4
Watch or listen to the newest EASL Studio Episode on “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance” from Wednesday, 26 Nov 2026.
#rifaximin #HepaticEncephalopathy #AntimicrobialResistance #cirrhosis #ACLF
The session will also be available to watch on demand on EASL Campus from Thursday, 27 November
👉 easlcampus.eu/easl-studio/...
Within MICROB-PREDICT, WP6 is uncovering the mechanisms by which rifaximin & albumin interact with the microbiome and the gut–liver axis, using cellular + rodent models.
On Wednesday, 26 Nov, at 6 pm CET, EASL Studio hosts a new episode titled “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance”
The episode will be broadcast live on EASL.eu and can be accessed here:
📹 easl.eu/easl-studio-...
Don't miss it ☺️
🎉 Our new #mirobiome paper in #JHEP is out! We found distinct gut #virome shifts in #ACLF - from virulent to temperate #phages - with Lactococcus A + Enterococcus B phages linked to infections & higher 90-day mortality
👉 Read more: www.sciencedirect.com/science/arti...
📽️Video: youtu.be/0YF6qToBQUM
